Eur J Nucl Med Mol Imaging (2017) 44 (Suppl 1):S84–S96 DOI 10.1007/s00259-017-3734-0 REVIEW ARTICLE Therapy assessment of bone metastatic disease in the era of radium 1 1 2 2 Elba Etchebehere & Ana Emilia Brito & Alireza Rezaee & Werner Langsteger & 2,3 Mohsen Beheshti Received: 10 May 2017 /Accepted: 12 May 2017 /Published online: 31 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract Introduction Purpose Defining an optimal imaging modality for assess- ment of therapy and the best time of evaluation are pivotal Prostate cancer is the second most common cancer among for ideal patient’smanagement. men and the sixth leading cause of cancer-related death world- Methods Ra (Xofigo®, formerly Alpharadin) has been ap- wide . It metastasizes to skeleton in approximately 65–75% proved by the FDA and European Medicines Agency for treat- of cases, which dramatically changes the outcome in these ment of metastatic castration-resistant prostate cancer with patients [2, 3]. To avoid related morbidities such as bone pain, painful osseous involvement. bone fracture and possible cord compression, it is crucial to Results PET/CT imaging using various radiotracers such as discover and manage the lesions early in the course of meta- 18 18 68 18 F–FDG, F–FCH, Ga-PSMA and
European Journal of Nuclear Medicine and Molecular Imaging – Springer Journals
Published: May 31, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera